LGVN Q1 2022 Earnings — Longeveron Inc. Revenue & Financial Results | Market Cap Arena

LGVNLongeveron Inc.

$20M

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$370,000-1.6% YoY

Gross Profit

$165,00044.6% margin

Operating Income

-$3M-917.3% margin

Net Income

-$4M-948.6% margin

EPS (Diluted)

$-1.70

QoQ Revenue Growth

+77.0%

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

-$4M

Stock-Based Comp.

$491,000

Balance Sheet

Total Assets

$39M

Total Liabilities

$5M

Stockholders' Equity

$34M

Cash & Equivalents

$22M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$370,000	$376,000	-1.6%
Gross Profit	$165,000	$149,000	+10.7%
Operating Income	-$3M	-$3M	+1.9%
Net Income	-$4M	-$3M	-12.8%